Published in Hepatology on April 01, 2009
Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85
Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology (2010) 2.68
Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology (2013) 2.21
Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats. Gastroenterology (2011) 1.85
Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology (2011) 1.63
Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol (2012) 1.57
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23
Hemodynamic alterations in cirrhosis and portal hypertension. Korean J Hepatol (2010) 1.18
Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology (2011) 1.17
Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Liver Int (2011) 1.12
Hepatopulmonary syndrome: update on pathogenesis and clinical features. Nat Rev Gastroenterol Hepatol (2012) 1.05
Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions. J Hepatol (2014) 1.04
Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J Clin Exp Hepatol (2014) 1.04
Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation. Cell Death Dis (2013) 0.98
Epithelial-mesenchymal transition: focus on metastatic cascade, alternative splicing, non-coding RNAs and modulating compounds. Mol Cancer (2013) 0.96
Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases. World J Gastroenterol (2010) 0.96
Angiogenesis and liver fibrosis. World J Hepatol (2015) 0.93
Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. PLoS One (2011) 0.92
Acute kidney injury in patients with cirrhosis: perils and promise. Clin Gastroenterol Hepatol (2013) 0.92
Current concepts on the role of nitric oxide in portal hypertension. World J Gastroenterol (2013) 0.92
Pathophysiology of portal hypertension. Clin Liver Dis (2014) 0.91
Vascular biology of the biliary epithelium. J Gastroenterol Hepatol (2013) 0.91
Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open (2016) 0.91
Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments. J Hepatol (2015) 0.90
The lung in liver disease: old problem, new concepts. Trans Am Clin Climatol Assoc (2013) 0.89
Vascular factors, angiogenesis and biliary tract disease. Curr Opin Gastroenterol (2010) 0.88
The chinese herbal decoction danggui buxue tang inhibits angiogenesis in a rat model of liver fibrosis. Evid Based Complement Alternat Med (2012) 0.88
The effect of antifibrotic drugs in rat precision-cut fibrotic liver slices. PLoS One (2014) 0.87
Physiopathology of splanchnic vasodilation in portal hypertension. World J Hepatol (2010) 0.87
Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study. J Gastroenterol (2012) 0.87
Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure. J Cell Mol Med (2012) 0.86
Promising Therapy Candidates for Liver Fibrosis. Front Physiol (2016) 0.85
Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology (2015) 0.85
Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis. PLoS One (2013) 0.83
Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress. World J Hepatol (2015) 0.82
New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials. Front Pharmacol (2016) 0.81
Antiangiogenic therapy: not just for cancer anymore? Hepatology (2009) 0.81
Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition. PLoS One (2015) 0.80
Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis. World J Gastroenterol (2015) 0.80
Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model. Braz J Med Biol Res (2015) 0.80
Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. Proc Natl Acad Sci U S A (2015) 0.79
Zolmitriptan: a novel portal hypotensive agent which synergizes with propranolol in lowering portal pressure. PLoS One (2013) 0.78
Risk factors of early re-bleeding and mortality in patients with ruptured gastric varices and concomitant hepatocellular carcinoma. J Gastroenterol (2012) 0.78
Combination of sorafenib and gadolinium chloride (GdCl3) attenuates dimethylnitrosamine(DMN)-induced liver fibrosis in rats. BMC Gastroenterol (2015) 0.78
New therapies for hepatic fibrosis. Clin Res Hepatol Gastroenterol (2015) 0.78
Bevacizumab attenuates hepatic fibrosis in rats by inhibiting activation of hepatic stellate cells. PLoS One (2013) 0.78
New Developments on the Treatment of Liver Fibrosis. Dig Dis (2016) 0.77
The role of receptor tyrosine kinase activation in cholangiocytes and pulmonary vascular endothelium in experimental hepatopulmonary syndrome. Am J Physiol Gastrointest Liver Physiol (2013) 0.77
Clinical Advancements in the Targeted Therapies against Liver Fibrosis. Mediators Inflamm (2016) 0.77
Rapamycin Attenuates Splenomegaly in both Intrahepatic and Prehepatic Portal Hypertensive Rats by Blocking mTOR Signaling Pathway. PLoS One (2016) 0.77
Thalidomide Improves the Intestinal Mucosal Injury and Suppresses Mesenteric Angiogenesis and Vasodilatation by Down-Regulating Inflammasomes-Related Cascades in Cirrhotic Rats. PLoS One (2016) 0.76
Aqueous Date Flesh or Pits Extract Attenuates Liver Fibrosis via Suppression of Hepatic Stellate Cell Activation and Reduction of Inflammatory Cytokines, Transforming Growth Factor- β 1 and Angiogenic Markers in Carbon Tetrachloride-Intoxicated Rats. Evid Based Complement Alternat Med (2015) 0.76
Multikinase inhibitor sorafenib prevents pressure overload-induced left ventricular hypertrophy in rats by blocking the c-Raf/ERK1/2 signaling pathway. J Cardiothorac Surg (2014) 0.76
Angiogenesis and Fibrogenesis in Chronic Liver Diseases. Cell Mol Gastroenterol Hepatol (2015) 0.76
Canonical hedgehog signaling regulates hepatic stellate cell-mediated angiogenesis in liver fibrosis. Br J Pharmacol (2017) 0.75
Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib. United European Gastroenterol J (2015) 0.75
Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law. Liver Cancer (2014) 0.75
Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis? Oncotarget (2016) 0.75
Future therapy of portal hypertension in liver cirrhosis - a guess. F1000Prime Rep (2014) 0.75
Hagen-Poiseuille's law: The link between cirrhosis, liver stiffness, portal hypertension and hepatic decompensation. World J Hepatol (2015) 0.75
Ischemia reperfusion of the hepatic artery induces the functional damage of large bile ducts by changes in the expression of angiogenic factors. Am J Physiol Gastrointest Liver Physiol (2015) 0.75
Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats. Angiogenesis (2016) 0.75
Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging. Eur Radiol (2017) 0.75
Novel treatment options for portal hypertension. Gastroenterol Rep (Oxf) (2017) 0.75
Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med (2010) 8.40
Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med (2005) 6.31
Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med (2010) 5.37
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology (2007) 4.09
Enigmatic Kikuchi-Fujimoto disease: a comprehensive review. Am J Clin Pathol (2004) 4.05
Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology (2012) 3.86
Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology (2015) 3.63
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology (2002) 3.50
Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. Hepatology (2013) 3.31
Multiple emergences of genetically diverse amphibian-infecting chytrids include a globalized hypervirulent recombinant lineage. Proc Natl Acad Sci U S A (2011) 2.78
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (2011) 2.42
Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology (2006) 2.39
Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology (2010) 2.39
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS (2004) 2.39
Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest (2011) 2.36
A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol (2008) 2.35
Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol (2009) 2.22
Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology (2007) 2.07
Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. Hepatology (2012) 2.03
Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology (2006) 2.03
Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology (2013) 1.93
Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol (2006) 1.90
Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut (2011) 1.87
Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol (2005) 1.87
Ciguatera fish poisoning: treatment, prevention and management. Mar Drugs (2008) 1.85
MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology (2003) 1.85
An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl (2007) 1.83
Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology (2009) 1.76
How to prevent varices from bleeding: shades of grey--the case for nonselective beta blockers. Gastroenterology (2007) 1.70
Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut (2011) 1.66
Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology (2003) 1.64
Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology (2011) 1.63
Mitigating amphibian disease: strategies to maintain wild populations and control chytridiomycosis. Front Zool (2011) 1.62
Effects of splenic artery occlusion on portal pressure in patients with cirrhosis and portal hypertension. Liver Transpl (2006) 1.60
Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol (2007) 1.60
Factors driving pathogenicity vs. prevalence of amphibian panzootic chytridiomycosis in Iberia. Ecol Lett (2010) 1.60
Cell-specific PPARγ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells. J Hepatol (2013) 1.55
Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. Hepatology (2011) 1.54
Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study. Hepatology (2010) 1.53
Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. J Hepatol (2010) 1.53
Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to endotoxin. J Hepatol (2007) 1.51
Portal hypertension and its complications. Gastroenterology (2008) 1.50
Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J (2006) 1.50
Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation. J Hepatol (2011) 1.50
Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology (2009) 1.49
Proteomic and phenotypic profiling of the amphibian pathogen Batrachochytrium dendrobatidis shows that genotype is linked to virulence. Mol Ecol (2009) 1.49
Portal hypertension in children: expert pediatric opinion on the report of the Baveno v Consensus Workshop on Methodology of Diagnosis and Therapy in Portal Hypertension. Pediatr Transplant (2012) 1.49
The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. J Hepatol (2012) 1.48
Chytrid fungus in Europe. Emerg Infect Dis (2005) 1.43
Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats. Hepatology (2014) 1.43
Use of noninvasive markers of portal hypertension and timing of screening endoscopy for gastroesophageal varices in patients with chronic liver disease. Hepatology (2013) 1.43
Non invasive evaluation of portal hypertension using transient elastography. J Hepatol (2011) 1.42
Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome. Hepatology (2006) 1.42
Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. Gastroenterology (2006) 1.41
Developments and controversies in the management of oesophageal and gastric varices. Gut (2010) 1.40
Portal hypertension and variceal bleeding--unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference. Hepatology (2008) 1.40
Cocaine-induced acute hepatitis and thrombotic microangiopathy. JAMA (2005) 1.39
[Liver abscesses following liver transplantation from non-heart-beating donation]. Med Clin (Barc) (2010) 1.39
A specialized, nurse-run titration clinic: a feasible option for optimizing beta-blockade in non-clinical trial patients. Am J Gastroenterol (2010) 1.38
[66-year-old woman presenting with asthenia and eosinophilia]. Med Clin (Barc) (2004) 1.38
[A 73-year-old male with protracted fever and alteration of hepatic parameters]. Med Clin (Barc) (2007) 1.38
Invasive pathogens threaten species recovery programs. Curr Biol (2008) 1.37
Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology (2004) 1.30
Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology (2002) 1.30
Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol (2012) 1.23
Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology (2007) 1.23
Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis. Hepatology (2008) 1.21
Endoscopic band ligation in the treatment of portal hypertension. Nat Clin Pract Gastroenterol Hepatol (2005) 1.20
The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation. FASEB J (2005) 1.19
Relative roles of ICAM-1 and VCAM-1 in the pathogenesis of experimental radiation-induced intestinal inflammation. Int J Radiat Oncol Biol Phys (2003) 1.19
Portal hypertension secondary to myelofibrosis: a study of three cases. Am J Gastroenterol (2005) 1.18
Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology (2004) 1.18
Assessing portal hypertension in liver diseases. Expert Rev Gastroenterol Hepatol (2013) 1.16
ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study. J Hepatol (2012) 1.15
Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J Neurosci (2010) 1.14
Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin Cancer Res (2004) 1.14
Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol (2009) 1.14
Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD. PLoS One (2012) 1.13
Environmental detection of Batrachochytrium dendrobatidis in a temperate climate. Dis Aquat Organ (2007) 1.11
New therapeutic paradigm for patients with cirrhosis. Hepatology (2012) 1.10
Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology (2010) 1.10
Extrahepatic portal vein thrombosis. Semin Liver Dis (2008) 1.08
Thyroid hormone activates oligodendrocyte precursors and increases a myelin-forming protein and NGF content in the spinal cord during experimental allergic encephalomyelitis. Proc Natl Acad Sci U S A (2002) 1.06
Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol (2007) 1.04
Insulin resistance and liver microcirculation in a rat model of early NAFLD. J Hepatol (2011) 1.01
Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. J Hepatol (2011) 1.01
Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology (2003) 1.00
Noninvasive prediction of clinically significant portal hypertension and esophageal varices in patients with compensated liver cirrhosis. Am J Gastroenterol (2008) 0.99
Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension. J Clin Gastroenterol (2005) 0.99
Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology (2004) 0.98
Context-dependent amphibian host population response to an invading pathogen. Ecology (2013) 0.98
PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology (2004) 0.98
Course of cognitive decline in hematopoietic stem cell transplantation: a within-subjects design. Arch Clin Neuropsychol (2009) 0.97